Hemoglobinopathies Market size is expected to witness significant growth from 2016 to 2023 - PowerPoint PPT Presentation

About This Presentation
Title:

Hemoglobinopathies Market size is expected to witness significant growth from 2016 to 2023

Description:

Hemoglobinopathies Market size was valued at over USD 4 billion in 2015. High occurrence in underdeveloped nations such as Arab nations, Sub-Saharan region and South East Asia is a major growth driver. – PowerPoint PPT presentation

Number of Views:46

less

Transcript and Presenter's Notes

Title: Hemoglobinopathies Market size is expected to witness significant growth from 2016 to 2023


1
Hemoglobinopathies Market Size, Industry Analysis
Report, Regional Outlook, Application Potential,
Price Trends, Competitive Market Share
Forecast, 2016 2023 Global Market Insights Inc.
Fuel Cell Market size worth 25.5bn by 2024
Low Power Wide Area Network
2
Regional Analysis of Hemoglobinopathies Market
  • Globally, incidence of thalassemia is about 0.2
    million patients, whereas sickle cell anemia has
    higher occurrence of around 20 million.
  • In 2015, North America was the largest revenue
    generating region with around USD 1.2 billion
    owing to rise in RD investments, better
    compensation state, and presence of high quality
    healthcare infrastructure.
  • Asia Pacific hemoglobinopathies market share is
    anticipated to increase at 9 CAGR due to rising
    patient awareness and introduction of
    manufactured and low cost diagnostic kits.
  • Sickle cell anemia is the most prevalentdisease
    in West Africa, with nearly 20 of people having
    sickle cell trait and about 2 of total babies
    born with a form of the disease. In many regions
    of Europe, hemoglobin (Hb) disorders are
    classified as prevalent diseases.

3
Application Analysis of Hemoglobinopathies
Market
  • Hemoglobinopathy is a group of inherited
    disorders caused due to abnormal production or
    aberration in hemoglobin structure.
  • Different disorders comprise sickle cell anemia,
    S-C and hemoglobin C disorder and various forms
    of thalassemia.
  • Originally found in the Mediterranean area and
    large parts of Asia and Africa, they now have
    presence across the globe on account of growing
    migration.
  • Most common tools/tests for diagnosis of
    hemoglobinopathies and thalassemia disorders are
    pre-implantation genetic diagnosis, genetic and
    blood testing, alkaline and acid gel
    electrophoresis, hemoglobin electrophoresis,
    prenatal genetic testing and HbA2 quantification
    by ion exchange column chromatography.

4
Competitive Market Share of Hemoglobinopathies
Market
  • Key industry players comprise Alnylam
    Pharmaceuticals, Gamida Cell, Biogen Idec,
    AcceleronPharma, Sangamo BioSciences, Anthera
    Pharmaceuticals, Global Blood Therapeutics,
    Genetix Pharmaceuticals, Mast Therapeutics,
    Prolong Pharmaceuticals, Emmaus Medical, Calgene
    Corporation, Invenux, Optinova Ab, and HemaQuest
    Pharmaceuticals.
  • Companies are aiming on the partnership and
    licensing deals for sharing the research and
    development platform. In 2014, Sangamo
    BioSciences and Biogen Idec declared
    collaboration agreement that targeted
    hemoglobinopathies market therapeutics
    development.

5

Browse Full Market Research Report On
Hemoglobinopathies Market _at_ https//www.gminsights
.com/industry-analysis/hemoglobinopathies-market
Request for an in-depth table of contents for
this report _at_ https//www.gminsights.com/request-t
oc/upcoming/470
6
Stay In Touch Website www.gminsights.com Soci
al Media
Write a Comment
User Comments (0)
About PowerShow.com